Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29094937 | 0.98 | CA2 (0.40) | CA2CA1 | |
| Ammonia Solution, Strong SCHEMBL28134013 | 0.98 | CA2 (0.40) | CA2CA1 | |
| SCHEMBL18856639 | 0.94 | CA2 (0.40) | CA2CA1 | |
| Methoxymethane SCHEMBL8159900 | 0.90 | CA2 (0.38) | CA2CA1 | |
| SCHEMBL1032931 | 0.87 | CA2 (0.47) | CA2CA1CA9 | |
| SCHEMBL18889097 | 0.86 | CA2 (0.39) | CA2CA1CA9 | |
| SCHEMBL7450593 | 0.86 | ALDH1A1 (0.41) | CA2CA1CA9 | |
| SCHEMBL28048598 | 0.83 | CA2 (0.37) | CA2CA1 | |
| Ethane Dimethane Sulfonate SCHEMBL8875130 | 0.81 | USP2 (0.50) | CA2CA1CA9 | |
| SCHEMBL4968127 | 0.80 | CA2 (0.34) | CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565505-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-09-11 | — | — | US | disclosed |
| CN-118184678-A | MTORC modulators and uses thereof | 艾奥维安制药公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240173305-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-30 | — | — | US | disclosed |
| EP-3813946-B1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-22 | — | — | EP | disclosed |
| EP-3383377-B1 | COMPOUNDS AND METHODS FOR INHIBITING PRODUCTION OF TRIMETHYLAMINE | PROCTER & GAMBLE (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117843659-A | Rapamycin analogues and uses thereof | 詹森药业有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-113766916-B | MTORC modulators and uses thereof | 艾奥维安制药公司 | 2024-04-05 | — | — | CN | disclosed |
| US-11944605-B2 | Rapamycin analogs and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-02 | — | — | US | disclosed |
| EP-4302827-A2 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN Pharmaceutica NV (BE) | 2024-01-10 | — | — | EP | disclosed |
| WO-2003091253-A1 | NITROSATED IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2003-11-06 | — | — | WO | disclosed |
| CN-1452620-A | Imidazolo-5-yl-2-anilino-pyrimidines as agents for inhibition of cell proliferation | ASTRAZENECA AB (CH) | 2003-10-29 | — | — | CN | disclosed |
| EP-1351958-A1 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1332143-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA Pharma AG (DE) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002034749-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2002-05-02 | — | — | WO | disclosed |
| WO-2002020512-A1 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
| CN-1231663-A | Arthropodicidal and fungicidal cyclic amides | DU PONT (US) | 1999-10-13 | — | — | CN | disclosed |
| EP-0934283-A2 | ARTHROPODICIDAL AND FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998005652-A2 | ARTHROPODICIDAL AND FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-02-12 | — | — | WO | disclosed |
| US-4732977-A | BACTERICIDES | BRISTOL MYERS COMPANY (US) | 1988-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | CA2 1924/4885CA1 4853/4885CA9 3355/4885 |
| US-12565505-B2 | mTORC modulators and uses thereof | RICTOR, MTOR, RPTOR | CA2 2121/4885CA1 4484/4885CA9 3889/4885 |
| US-11944605-B2 | Rapamycin analogs and uses thereof | RICTOR, MTOR, RPTOR | CA2 4583/4885CA1 4755/4885CA9 4287/4885 |
| US-20240173305-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | CA2 4583/4885CA1 4755/4885CA9 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.